在耐火性巨细胞动脉炎中使用upadacitinib:一个案例报告
Lisa Wang1,2, Christopher Davidson3, Brian Wu1
1Department of Medicine, Division of Rheumatology, Queen's University, Kingston, Ontario, Canada.
Modern rheumatology case reports
|August 2, 2025
概括
乌帕达西替尼 (UPA) 在对标准治疗无反应的患者治疗巨细胞动脉炎 (GCA) 方面表现有前途. 本案例报告强调了UPA在改善GCA耐药患者的症状和生活质量的有效性.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 巨细胞动脉炎 (GCA) 是一种影响老年人的自身免疫性血管炎,主要用葡萄糖皮质类药物治疗.
- 对GCA的葡萄糖皮质激素单一治疗有局限性,包括不充分的爆发预防和显著的长期副作用.
- 托西利祖马布 (TCZ) 是一种替代药物,但在某些患者中可能不足或引起不良事件.
研究的目的:
- 报告Janus激酶 (JAK) 抑制剂upadacitinib (UPA) 的疗效,该疗效用于患有GCA耐普得尼松和TCZ耐火症的患者.
- 评估UPA作为GCA患者的潜在治疗选择,这些患者已经失败或对现有疗法不耐受.
主要方法:
- 一个82岁的女性患有GCA的病例报告.
- 患者对普得尼松耐药,并经历了TCZ的严重副作用.
- 开始治疗时使用乌帕达西提尼布 (UPA).
主要成果:
- 乌帕达西尼布 (UPA) 治疗导致GCA症状的显著改善,包括头痛和疲劳.
- 患者经历了UPA的最小的不良事件.
- 这一结果表明UPA在管理耐火GCA方面的潜力.
结论:
- 乌帕达西替尼 (UPA) 可能是巨细胞动脉炎 (GCA) 患者的可行和有效治疗方法,这些患者对当前治疗不反应或不耐受.
- 对GCA的UPA的真实数据很少,需要进一步调查.
- 需要进行额外的研究来确认UPA在GCA管理中的长期安全性和有效性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...


